Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 95

1.

Deregulation of innate immune signaling in myelodysplastic syndromes is associated with deletion of chromosome arm 5q.

Starczynowski DT, Karsan A.

Cell Cycle. 2010 Mar 1;9(5):855-6. Epub 2010 Mar 11. No abstract available.

PMID:
20160505
2.

Coordinate loss of a microRNA and protein-coding gene cooperate in the pathogenesis of 5q- syndrome.

Kumar MS, Narla A, Nonami A, Mullally A, Dimitrova N, Ball B, McAuley JR, Poveromo L, Kutok JL, Galili N, Raza A, Attar E, Gilliland DG, Jacks T, Ebert BL.

Blood. 2011 Oct 27;118(17):4666-73. doi: 10.1182/blood-2010-12-324715. Epub 2011 Aug 26.

3.

Deletion 5q MDS: molecular and therapeutic implications.

Komrokji RS, Padron E, Ebert BL, List AF.

Best Pract Res Clin Haematol. 2013 Dec;26(4):365-75. doi: 10.1016/j.beha.2013.10.013. Epub 2013 Oct 16. Review.

PMID:
24507813
4.

[Ribosomal protein in impaired erythropoiesis: Diamond-Blackfan anemia and 5q- syndrome].

Ito E.

Rinsho Ketsueki. 2009 Oct;50(10):1539-47. Review. Japanese. No abstract available.

PMID:
19915364
5.

Errant innate immune signaling in del(5q) MDS.

Starczynowski DT.

Blood. 2014 Jul 31;124(5):669-71. doi: 10.1182/blood-2014-06-581728.

6.

Fluorescence in situ hybridization improves the detection of 5q31 deletion in myelodysplastic syndromes without cytogenetic evidence of 5q-.

Mallo M, Arenillas L, Espinet B, Salido M, Hernández JM, Lumbreras E, del Rey M, Arranz E, Ramiro S, Font P, González O, Renedo M, Cervera J, Such E, Sanz GF, Luño E, Sanzo C, González M, Calasanz MJ, Mayans J, García-Ballesteros C, Amigo V, Collado R, Oliver I, Carbonell F, Bureo E, Insunza A, Yañez L, Muruzabal MJ, Gómez-Beltrán E, Andreu R, León P, Gómez V, Sanz A, Casasola N, Moreno E, Alegre A, Martín ML, Pedro C, Serrano S, Florensa L, Solé F.

Haematologica. 2008 Jul;93(7):1001-8. doi: 10.3324/haematol.13012.

7.

Haploinsufficiency of RPS14 in 5q- syndrome is associated with deregulation of ribosomal- and translation-related genes.

Pellagatti A, Hellström-Lindberg E, Giagounidis A, Perry J, Malcovati L, Della Porta MG, Jädersten M, Killick S, Fidler C, Cazzola M, Wainscoat JS, Boultwood J.

Br J Haematol. 2008 Jul;142(1):57-64. doi: 10.1111/j.1365-2141.2008.07178.x. Epub 2008 May 8. Erratum in: Br J Haematol. 2009 Feb;144(3):455.

8.

The 5q- syndrome: a scientific and clinical update.

Tefferi A, Mathew P, Noël P.

Leuk Lymphoma. 1994 Aug;14(5-6):375-8. Review.

PMID:
7812195
9.

Transcription factors Fli1 and EKLF in the differentiation of megakaryocytic and erythroid progenitor in 5q- syndrome and in Diamond-Blackfan anemia.

Neuwirtova R, Fuchs O, Holicka M, Vostry M, Kostecka A, Hajkova H, Jonasova A, Cermak J, Cmejla R, Pospisilova D, Belickova M, Siskova M, Hochova I, Vondrakova J, Sponerova D, Kadlckova E, Novakova L, Brezinova J, Michalova K.

Ann Hematol. 2013 Jan;92(1):11-8. doi: 10.1007/s00277-012-1568-1. Epub 2012 Sep 11.

PMID:
22965552
10.

Cytogenetic features of 5q deletion and 5q- syndrome in myelodysplastic syndrome in Korea; marker chromosomes proved to be chromosome 5 with interstitial deletion by fluorescence in situ hybridization.

Lee HR, Oh B, Hong DS, Zang DY, Yoon HJ, Kim HJ, Kim I, Ahn JS, Cheong JW, Lee KA, Cho KS, Lee MH, Bang SM, Kim TY, Yun YM, Min YH, Lee YK, Lee DS; AML/MDS Working Party of the Korean Society of Hematology.

Cancer Genet Cytogenet. 2010 Dec;203(2):193-202. doi: 10.1016/j.cancergencyto.2010.08.007.

PMID:
21156233
11.

MDS with del(5q) and associated cKIT D816V positive mastocytosis.

Chan N, Tan SY, Opat S, Shortt J.

Pathology. 2012 Aug;44(5):492-3. doi: 10.1097/PAT.0b013e3283559d03. No abstract available.

PMID:
22777071
12.

Initial experience with L-leucine therapy in myelodysplastic syndromes with associated chromosome 5q deletion.

Steensma DP, Ebert BL.

Blood. 2013 May 23;121(21):4428. doi: 10.1182/blood-2013-03-493809. No abstract available.

13.
14.

[Myelodysplastic syndrome associated with 5q deletion, review of 3 cases].

Khanfir A, Frikha M, Mseddi S, Elloumi M, Daoud J, Makni F, Amouri A, Gargouri J, Saad A, Souissi T.

Tunis Med. 1997 Mar;75(3):127-31. French. No abstract available.

PMID:
9506035
15.

Changes in RPS14 expression levels during lenalidomide treatment in Low- and Intermediate-1-risk myelodysplastic syndromes with chromosome 5q deletion.

Oliva EN, Cuzzola M, Nobile F, Ronco F, D'Errigo MG, Laganà C, Morabito F, Galimberti S, Cortelezzi A, Aloe Spiriti MA, Specchia G, Poloni A, Breccia M, Ghio R, Finelli C, Iacopino P, Alimena G, Latagliata R.

Eur J Haematol. 2010 Sep;85(3):231-5. doi: 10.1111/j.1600-0609.2010.01473.x. Epub 2010 May 17.

PMID:
20491881
16.

Biological activity of lenalidomide in myelodysplastic syndromes with del5q: results of gene expression profiling from a multicenter phase II study.

Oliva EN, Cuzzola M, Aloe Spiriti MA, Poloni A, Laganà C, Rigolino C, Morabito F, Galimberti S, Ghio R, Cortelezzi A, Palumbo GA, Sanpaolo G, Finelli C, Ricco A, Volpe A, Rodà F, Breccia M, Alimena G, Nobile F, Latagliata R.

Ann Hematol. 2013 Jan;92(1):25-32. doi: 10.1007/s00277-012-1569-0. Epub 2012 Sep 16.

PMID:
22983750
17.

5q- syndrome.

Boultwood J, Pellagatti A, Wainscoat JS.

Curr Pharm Des. 2012;18(22):3180-3. Review.

PMID:
22571696
18.

What lies beyond del(5q) in myelodysplastic syndrome?

Adema V, Bejar R.

Haematologica. 2013 Dec;98(12):1819-21. doi: 10.3324/haematol.2013.094912. No abstract available.

19.

Induction of p53 and up-regulation of the p53 pathway in the human 5q- syndrome.

Pellagatti A, Marafioti T, Paterson JC, Barlow JL, Drynan LF, Giagounidis A, Pileri SA, Cazzola M, McKenzie AN, Wainscoat JS, Boultwood J.

Blood. 2010 Apr 1;115(13):2721-3. doi: 10.1182/blood-2009-12-259705. No abstract available.

PMID:
20360478
20.

The role of lenalidomide in the treatment of patients with chromosome 5q deletion and other myelodysplastic syndromes.

Melchert M, Kale V, List A.

Curr Opin Hematol. 2007 Mar;14(2):123-9. Review.

PMID:
17255789

Supplemental Content

Support Center